{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:17:28Z","timestamp":1781245048868,"version":"3.54.1"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T00:00:00Z","timestamp":1316390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p><jats:bold>Background\/Objectives\u2002<\/jats:bold> Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by intravascular haemolysis with a negative direct antiglobulin test (DAT). Eculizumab is a humanized monoclonal antibody that inhibits complement component C5 and is approved for PNH treatment. Recent publications demonstrated that some patients with PNH develop a positive DAT during eculizumab treatment. These published clinical trials investigated a highly selected patient population. Therefore, it seems important to study this topic in a general PNH patient population with a longer follow\u2010up.<\/jats:p><jats:p><jats:bold>Materials and Methods\u2002<\/jats:bold> We analysed haemolytic activity, RBC transfusion requirement, effect on DAT and ferritin levels in 41 patients with PNH before and during eculizumab therapy with a median follow\u2010up of 24\u2003months (range 1\u201363\u2003months).<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> During eculizumab therapy, median LDH decreased (1657\u2013258\u2003U\/l; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001), while median haemoglobin increased (9\u00b72\u201310\u00b73\u2003g\/dl). Eighteen of 32 pts (56%) who previously required regular transfusions became transfusion independent. DAT was positive for C3d in 72\u00b74% of 21 eculizumab\u2010treated pts with available DAT. Ferritin levels increased (69\u2013348\u2003ng\/ml, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001). This increase was more pronounced in pts with ongoing transfusion dependency during eculizumab therapy.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Eculizumab therapy for PNH should be added to the list of possible causes for a positive DAT. Intravascular haemolysis was inhibited by eculizumab, but signs of extravascular haemolysis should be monitored. Because renal iron loss was stopped, eculizumab\u2010treated pts can be prone to iron overload and therefore ferritin concentrations should be monitored closely.<\/jats:p>","DOI":"10.1111\/j.1423-0410.2011.01530.x","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T19:22:19Z","timestamp":1316460139000},"page":"159-166","source":"Crossref","is-referenced-by-count":36,"title":["Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test"],"prefix":"10.1111","volume":"102","author":[{"given":"B.","family":"H\u00f6chsmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Leichtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"von Zabern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. A.","family":"Flegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,19]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/003591576305600723"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V36.2.145.145"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7680492"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2095"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511093331904"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1717"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1344"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094136"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031688"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095646"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1005108"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.007229"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-189944"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2.1.7"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.017848"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054924"}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1423-0410.2011.01530.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1423-0410.2011.01530.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T02:36:13Z","timestamp":1698633373000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1423-0410.2011.01530.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,19]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1111\/j.1423-0410.2011.01530.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1423-0410.2011.01530.x","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,19]]}}}